BIOMAT Database Logo BIOMAT Database Logo

A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years. 1988

C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Department of Surgery, University of Minnesota, Minneapolis.

Between September 1980 and June 1984, 246 splenectomized, transfused renal allograft recipients were stratified according to presence of diabetes and donor source, and randomized to treatment with either cyclosporine (CsA)-prednisone (pred) or antilymphoblast-globulin (ALG--azathioprine (AZA)--prednisone. As of August 1986, mean follow-up is 47 months. Over all, actuarial patient survival is 84% and 83%, respectively at 4 years. Corresponding graft survival is 70% and 63% for CsA-treated and ALG-AZA-treated patients (NS). Within the subgroup of diabetic recipients of cadaver grafts, graft survival is 70% for CsA-treated and 53% for ALG-AZA-treated recipients (P = .035). In the CsA group, 71% required either a significant reduction in CsA dosage with the addition of azathioprine or a complete switch to azathioprine, mainly because of CsA-associated nephrotoxicity. Of those CsA patients switched at a mean time of 21.3 +/- 16.4 months posttransplant with mean serum creatinine of 2.40 +/- .67, current serum creatinine is 1.79 +/- .63. Current mean serum creatinine values are significantly greater for patients randomized to CsA-pred (1.73 +/- .60) vs. ALG-AZA-pred (1.49 +/- .59), P = .014, even though most CsA-treated patients were eventually switched. The causes of graft loss are not different between CsA and ALG-AZA randomized patients. In nondiabetics, rejection is the most common cause of graft loss (17/33), whereas in diabetics loss due to complications from overimmunosuppression or death from cardiovascular events is significantly more common (27/44) than corresponding losses in nondiabetics (6/33, P less than .05). Switching does not seem to influence the incidence or cause of graft loss. Since most patients started on CsA-prednisone are ultimately switched to triple drug therapy, the latter is now the preferred initial treatment modality.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
June 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Pulmonary infections. The Minnesota randomized prospective trial of cyclosporine vs azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
September 1986, Archives of surgery (Chicago, Ill. : 1960),
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Antilymphoblast globulin for renal allograft prolongation.
December 1972, Transplantation proceedings,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Improved results of cadaver renal transplantation with azathioprine, prednisone and antilymphoblast globulin.
April 1984, The Journal of urology,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients. Data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine.
November 1987, American journal of surgery,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Sequential antilymphoblast globulin and cyclosporine for renal transplantation.
February 1987, Transplantation proceedings,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Sequential antilymphoblast globulin and cyclosporine for renal transplantation.
January 1987, Transplantation,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
February 1985, Annals of surgery,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Thromboembolic complications in renal allograft recipients. A report from the prospective randomized study of cyclosporine versus azathioprine-antilymphocyte globulin.
December 1987, Transplantation,
C P Johnson, and R L Simmons, and D E Sutherland, and D M Canafax, and N L Ascher, and W D Payne, and B Flick, and J S Najarian, and D S Fryd
Preliminary results of a randomized comparison of cyclosporine and Minnesota Antilymphoblast Globulin.
December 1982, Transplantation proceedings,
Copied contents to your clipboard!